Category: 34968-33-7

On December 16, 1971, Nicolson, Adrian published a patent.Application of 34968-33-7 The title of the patent was Chlorofluoropyridines. And the patent contained the following:

The title compounds were prepared by fluorination of chloropyridines with KF or NaF in a nonhydroxylic solvent, e.g. tetramethylene sulfone (I) or AcNMe2, in the presence of alcs., acids, or bases, e.g. MeOH, HO(CH2)2OH, glycerol, EtCO2H, or Bu3N. Thus, pentachloropyridine was added to KF (1:5.7 mole %) in I. ClCH2CO2H was added and the mixture refluxed 2 hr to give 79% fluorinated pyridines consisting of 3,5-dichlorotrifluoropyridine 97.5, pentafluoropyridine+3-chlorotetrafluoropyridine 2.2, and 3,5,6-tri-chlorodifluoropyridine 0.4%. Similarly prepared were 4-chloro-2-fluoro-, 2-chloro-4-fluoro-, 2,4-difluoro-, 6-chloro-2,4-difluoro,-and 4-chloro-2,6-difluoropyridine. The experimental process involved the reaction of 4-Chloro-2,6-difluoropyridine(cas: 34968-33-7).Application of 34968-33-7

The Article related to chlorofluoropyridine preparation, fluorochloropyridine preparation, pyridine chlorofluoro preparation, fluorination and other aspects.Application of 34968-33-7

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On October 1, 2018, Shinozuka, Tsuyoshi; Tsukada, Tomoharu; Fujii, Kunihiko; Tokumaru, Eri; Shimada, Kousei; Onishi, Yoshiyuki; Matsui, Yumi; Wakimoto, Satoko; Kuroha, Masanori; Ogata, Tsuneaki; Araki, Kazushi; Ohsumi, Jun; Sawamura, Ryoko; Watanabe, Nobuaki; Yamamoto, Hideki; Fujimoto, Kazunori; Tani, Yoshiro; Mori, Makoto; Tanaka, Jun published an article.Safety of 4-Chloro-2,6-difluoropyridine The title of the article was Discovery of DS-6930, a potent selective PPARγ modulator. Part II: Lead optimization. And the article contained the following:

Attempts were made to reduce the lipophilicity of previously synthesized compound (II) for the avoidance of hepatotoxicity. The replacement of the left-hand side benzene with 2-pyridine resulted in the substantial loss of potency. Because poor membrane permeability was responsible for poor potency in vitro, the adjustment of lipophilicity was examined, which resulted in the discovery of di-Me pyridine derivative (I, DS-6930). In preclin. studies, DS-6930 demonstrated high PPARγ agonist potency with robust plasma glucose reduction DS-6930 maintained diminished PPARγ-related adverse effects upon toxicol. evaluation in vivo, and demonstrated no hepatotoxicity. Cofactor recruitment assay showed that several cofactors, such as RIP140 and PGC1, were significantly recruited, whereas several canonical factors was not affected. This selective cofactor recruitment was caused due to the distinct binding mode of DS-6930. The calcium salt, DS-6930b, which is expected to be an effective inducer of insulin sensitization without edema, could be evaluated clin. in T2DM patients. The experimental process involved the reaction of 4-Chloro-2,6-difluoropyridine(cas: 34968-33-7).Safety of 4-Chloro-2,6-difluoropyridine

The Article related to ds 6930 preparation ppar modulator diabetes, benzimidazole, ds-6930, pparγ, Pharmacology: Structure-Activity and other aspects.Safety of 4-Chloro-2,6-difluoropyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On January 23, 1974, Bowden, Roy D.; Seaton, Thomas published a patent.Safety of 4-Chloro-2,6-difluoropyridine The title of the patent was Chlorofluoropyridines. And the patent contained the following:

Chlorofluoropyridines were prepared by vaporization of CCl4, CCl3F, or F2ClCCFCl2 solutions of fluoropyridines at 290-350° with solvent and reactant feed rates 0.18-0.6 and 0.025-0.125 mole/hr, resp., and contacting the vapor with Cl feed rate 0.5-1.10 mole/hr at 335-695° for 9.0-25.0 sec. Thus, CCl4 solution of 2-fluoropyridine, feed rates 0.3 and 0.025 mole/hr, resp., was vaporized at 290° and the vapor contacted with Cl feed rate 0.52 mole/hr at 375° for 23.5 sec to give 70% 6-chloro-2-fluoropyridine and traces of 5,6-, 4,6-, and 3,6-dichloro-2-fluoropyridines. The experimental process involved the reaction of 4-Chloro-2,6-difluoropyridine(cas: 34968-33-7).Safety of 4-Chloro-2,6-difluoropyridine

The Article related to chlorofluoropyridine, pyridine chlorofluoro, chlorination fluoropyridine, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Safety of 4-Chloro-2,6-difluoropyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On April 24, 2014, Xu, Wei; Wang, Yong; Ma, Sunghoon; Koltun, Elena S.; Kim, Byung Gyu; Jeong, Joon Won; Dhar, T.g. Murali; Bannen, Lynn Canne published a patent.Recommanded Product: 4-Chloro-2,6-difluoropyridine The title of the patent was Pyrimidine derivatives as RORγ modulators and their preparation. And the patent contained the following:

Described are RORγ modulators of formula I, and N-oxides, pharmaceutically acceptable salts, solvates and hydrates thereof, and their compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune. Compounds of formula I wherein R1 is H, halo, CN, NO2, OH, etc.; dashed bonds are single and double bond; R2 is H, halo, CN, NO2, N3, etc.; R4 and R5 are independently H, Me and F; m and n are independently 0, 1, 2, and 3; each R6 is halo, CN, NO2, N3, OH, etc.; each Ra is H, halo, CN, NO2, etc.; Z is CO, CS, SO2 and CH2; G is a single bond, CH2, CHD, CD2, etc.; B is Ph, pyridyl, naphthyl, thiazolyl and pyrimidinyl; L is CONHCH2, CONHCH2CH2O, oxadiazolyl, etc.; A is Ph, pyridyl, pyrimidinyl, thiazolyl, pyrazolyl and pyrazinyl; and stereoisomeric forms, N-oxides, pharmaceutically acceptable salts, solvates and hydrates thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compounds were evaluated for their RORγ modulatory activity. From the assay, it was determined that compound II exhibited IC50 value of 4.7 nM. The experimental process involved the reaction of 4-Chloro-2,6-difluoropyridine(cas: 34968-33-7).Recommanded Product: 4-Chloro-2,6-difluoropyridine

The Article related to pyrimidine preparation rorgamma modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Recommanded Product: 4-Chloro-2,6-difluoropyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On April 24, 2014, Xu, Wei; Wang, Yong; Ma, Sunghoon; Koltun, Elena S.; Kim, Byung Gyu; Jeong, Joon Won; Dhar, T.g. Murali; Bannen, Lynn Canne published a patent.Recommanded Product: 4-Chloro-2,6-difluoropyridine The title of the patent was Pyrimidine derivatives as RORγ modulators and their preparation. And the patent contained the following:

Described are RORγ modulators of formula I, and N-oxides, pharmaceutically acceptable salts, solvates and hydrates thereof, and their compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune. Compounds of formula I wherein R1 is H, halo, CN, NO2, OH, etc.; dashed bonds are single and double bond; R2 is H, halo, CN, NO2, N3, etc.; R4 and R5 are independently H, Me and F; m and n are independently 0, 1, 2, and 3; each R6 is halo, CN, NO2, N3, OH, etc.; each Ra is H, halo, CN, NO2, etc.; Z is CO, CS, SO2 and CH2; G is a single bond, CH2, CHD, CD2, etc.; B is Ph, pyridyl, naphthyl, thiazolyl and pyrimidinyl; L is CONHCH2, CONHCH2CH2O, oxadiazolyl, etc.; A is Ph, pyridyl, pyrimidinyl, thiazolyl, pyrazolyl and pyrazinyl; and stereoisomeric forms, N-oxides, pharmaceutically acceptable salts, solvates and hydrates thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compounds were evaluated for their RORγ modulatory activity. From the assay, it was determined that compound II exhibited IC50 value of 4.7 nM. The experimental process involved the reaction of 4-Chloro-2,6-difluoropyridine(cas: 34968-33-7).Recommanded Product: 4-Chloro-2,6-difluoropyridine

The Article related to pyrimidine preparation rorgamma modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Recommanded Product: 4-Chloro-2,6-difluoropyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Kolar, Michal; Hostas, Jiri; Hobza, Pavel published an article in 2015, the title of the article was The strength and directionality of a halogen bond are co-determined by the magnitude and size of the σ-hole [Erratum to document cited in CA160:690906].Name: 4-Chloro-2,6-difluoropyridine And the article contains the following content:

Corrections are provided for the misuse of the term “directionality”; the numerical results are unaffected. The experimental process involved the reaction of 4-Chloro-2,6-difluoropyridine(cas: 34968-33-7).Name: 4-Chloro-2,6-difluoropyridine

The Article related to erratum halogen bond strength directionality, sigma hole magnitude size effect erratum, Physical Organic Chemistry: Theoretical Organic Chemical Concepts, Including Quantum and Molecular Mechanical Studies and other aspects.Name: 4-Chloro-2,6-difluoropyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Kolar, Michal; Hostas, Jiri; Hobza, Pavel published an article in 2014, the title of the article was The strength and directionality of a halogen bond are co-determined by the magnitude and size of the σ-hole.Category: pyridine-derivatives And the article contains the following content:

The σ-holes of halogen atoms on various aromatic scaffolds were described in terms of their size and magnitude. The electrostatic potential maps at the CAM-B3LYP-D3(bj)/def2-QZVP level were calculated and the σ-holes of >100 aromatic analogs were thoroughly analyzed to relate the σ-holes to the binding preferences of the halogenated compounds Both the size and magnitude of the σ-hole increase when passing from chlorinated to iodinated analogs. Also, the σ-hole properties were studied upon chem. substitution of the aromatic ring as well as in the aromatic ring. Further, the angular variations of the interactions were studied on a selected set of halogenbenzene complexes with argon and hydrogen fluoride (HF). To analyze interaction energy components, DFT-SAPT angular scans were performed. The interaction energies of bromobenzene complexes were evaluated at the CCSD(T)/complete basis set level providing the benchmark energetic data. The strength of the halogen bond between halogenbenzenes and Ar atoms and HF mols. increases while its directionality decreases when passing from chlorine to iodine. The decrease of the directionality of the halogen bond is larger for a HF-containing complex and is caused by electrostatic and exchange-repulsion energies. These findings are especially valuable for protein-halogenated ligand-binding studies, applied in the realm of rational drug development and lead optimization. The experimental process involved the reaction of 4-Chloro-2,6-difluoropyridine(cas: 34968-33-7).Category: pyridine-derivatives

The Article related to halogen bond strength directionality sigma hole magnitude size effect, Physical Organic Chemistry: Theoretical Organic Chemical Concepts, Including Quantum and Molecular Mechanical Studies and other aspects.Category: pyridine-derivatives

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem